260660 — Korea Arlico Pharm Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩76bn
- KR₩92bn
- KR₩187bn
- 40
- 57
- 11
- 24
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | ARS | Annual Audited Accounts |
Standards: | IFRS | IFRS | — | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 37,093 | 19,516 | 28,747 | 32,203 | 30,790 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 20,277 | 19,359 | 19,379 | 19,997 | 22,536 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 70,099 | 57,984 | 68,855 | 82,123 | 83,555 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 19,443 | 26,661 | 31,641 | 49,726 | 66,740 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 118,754 | 110,288 | 121,062 | 153,536 | 173,477 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 36,887 | 26,980 | 33,770 | 57,258 | 70,320 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 47,468 | 32,721 | 39,933 | 64,990 | 84,402 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 71,286 | 77,566 | 81,129 | 88,546 | 89,075 |
Total Liabilities & Shareholders' Equity | 118,754 | 110,288 | 121,062 | 153,536 | 173,477 |
Total Common Shares Outstanding |